Search This Blog

Thursday, July 13, 2023

Biofrontera: Prelim Q2 Revenue Up 26% to 31%

 Management Reaffirms Full-Year 2023 Revenue Growth of at least 25% over Prior Year

Biofrontera Inc. (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, today announced preliminary unaudited revenues for the three months ended June 30, 2023.

Revenues for the second quarter of 2023 are anticipated to be in the range of approximately $5.7 million to $5.9 million, an increase of approximately 26% to 31% compared with the second quarter of 2022. As a result, revenues for the first half of 2023 are anticipated to be in the range of approximately $14.4 million to $14.6 million, representing growth of approximately 1% to 3% compared with the first half of 2022.

https://finance.yahoo.com/news/biofrontera-inc-announces-preliminary-second-130000893.html

Medical Costs In Focus For UnitedHealth Group’s Q2

 UnitedHealth Group (NYSE: UNH) is scheduled to report its Q2 2023 results on Friday, July 14. We expect UnitedHealth to post revenue and earnings in line with the street expectations. The company will likely continue to benefit from the increased contribution of the Optum Health business, while its health insurance business should benefit from increased memberships. Investors will be closely monitoring the medical costs in Q2, as the company’s management expects a rise in this metric in the near term. Not only do we expect the company to navigate well over the latest quarter, our forecast indicates that UNH stock is undervalued, as discussed below. Our interactive dashboard analysis of UnitedHealth’s Earnings Preview has additional details.

(1) Optum Health To Continue To Drive Top-Line Growth

  • Trefis estimates UnitedHealth’s Q2 2023 net revenues to be around $91 billion, reflecting a 14% y-o-y growth and aligning with the consensus estimate.
  • The health insurance business is expected to see steady sales growth led by an increase in total membership.
  • Optum Health, which provides care through local medical groups, has led the company’s top-line growth in recent quarters, a trend expected to continue in Q2.
  • The strong growth in the Optum Health business can be attributed to a rise in the number of patients served under the company’s value-based arrangements, including at-home services.
  • Optum Insight segment should benefit from the Change Healthcare acquisition in Q4 2022.
  • Our dashboard on UnitedHealth Group Revenues has more details on the company’s segments.
  • Looking at Q1 2023, UnitedHealth reported a 15% rise in total revenue, led by double-digit gains for both UnitedHealth and Optum segments.

(2) EPS likely to align with the consensus estimates

  • UnitedHealth’s Q2 2023 adjusted earnings per share is expected to be $6.10 per Trefis analysis, just four cents above the consensus estimate of $6.06.
  • UnitedHealth’s adjusted net income of $5.9 billion in Q1 2023 reflected a 13% rise from its $5.2 billion figure in the prior-year quarter, led by 14% sales growth partly offset by a slight decline in net margin. On a reported basis, operating margin expanded ten bps to 8.8% in Q1 2023. Our dashboard on UnitedHealth’s Operating Income has more details.
  • Last month, the company’s management stated that there is a rise in medical costs as more people are getting elective procedures that were earlier postponed during the pandemic. This is likely to weigh on the bottom line in the near term.
  • UnitedHealth’s medical care ratio stood at 82.2% in Q1 2023. compared to 82.0% in the prior-year quarter.
  • For the full-year 2023, we expect the adjusted EPS to be higher at $25.00 compared to $22.19 in 2022.
(3) UNH Stock Is Undervalued

  • We estimate UnitedHealth Group’s Valuation to be around $600 per share, reflecting a 30% upside from the current market price of $462.
  • This represents a 24x forward P/E multiple based on our earnings forecast of $25.00 on a per-share and adjusted basis and compares with the last three-year average P/E multiple of 21x. Given the double-digit earnings growth seen in recent years, we have assigned a higher P/E multiple for UNH compared to its historical average. This trend is expected to continue in the near term.
  • UNH stock has seen a 6% fall in a month, primarily due to the company’s management talking about the expected rise in medical costs.

While UNH stock can see higher levels, it is helpful to see how UnitedHealth Group Peers fare on metrics that matter.

https://www.forbes.com/sites/greatspeculations/2023/07/11/medical-costs-in-focus-for-unitedhealth-groups-q2/

Americans Now Cutting Back on Food Purchases, Conagra CEO Says

 The resilient American shopper is showing more signs of weakness.

Over the past year, many US consumers responded to surging inflation by trading down to cheaper options. But now they’re just going without, said Sean Connolly, chief executive officer of Conagra Brands Inc., during an earnings call. The behavioral shift began shortly after the Easter holiday in early April, he said.

“Importantly, where we see it, it is usually not a trade down to lower-priced alternatives within the category; rather, it’s an overall category slowdown,” he said. Connolly added that he expects the behavior is short term and that “people aren’t eating less.”

Read More: In Troubling Sign, Shoppers Skimp on Toothpaste

Certain grocery categories are feeling the pullback more than others, according to data from researcher NIQ. In food, overall units sold are down 2% this year, with some of the biggest declines coming in frozen meals, fruit juice and soup.

People are likely “burning through inventory in their homes,” said NIQ’s Carman Allison. “We’re spending more, but we’re buying less.”

Conagra’s results point to the dilemma facing consumer-focused companies that have relied on price increases to make up for softness in the number of items they’ve been selling. In the quarter ended May 28, the owner of the Slim Jim brand reported a 7.7% drop in volume, but revenue rose 2.2% thanks largely to higher prices.

In an interview, Connolly said that Americans are away from home more often and shifting spending to other categories.

“The consumer is very creative and very crafty in terms of finding ways to stretch their budget,” he said. “One of the ways they make that happen is they just cut back temporarily on the stuff that they buy in order to be able to fund other expenses. That’s what we believe.”

Even If Jerome Powell Is Successful, We Still Lose

 by Jeffrey Snider via RealClearMarkets.com,

In some ways it has been like two heavyweight sluggers battling it out over the course of an extended bout, exchanging one haymaker after another. With each monstrous blow, the receiver is staggered temporarily only to reform and then unleash one of his own. Back and forth, back and forth until such time a winner will be declared - and we all lose.

I hesitate to elevate the Fed and its rate-hiking regime to the status of a serious challenger, though it qualifies for any short run period.

Offering alternative money rates, the only real program policymakers have, they can influence the real champion, the bond market’s behavior. Somewhat.

If you own or are thinking of buying a 2-year US Treasury note, you’ll pay closer attention than someone thinking, say, ten years to what money market rates are now and what they could be over those relatively short two years. Using its reverse repo and even to an extent interest on reserves (they’re all excess nowadays), officials more directly impact all kinds of money rates.

But where Alan Greenspan once believed (his “conundrum”) a direct line (series of one-year forwards) existed rigidly linking every maturity and yield from there on down to the long bond, history has proven time and time again it gets real murky really quick.

Somewhere around that 2-year spot.

The fight began straight away, too, going back to the very day when Chairman Jay Powell abruptly decided in late 2021 “inflation” wasn’t transitory any longer. Whether politics or bad economics (using even worse Economics), the bond market disagreed it was ever inflation (recognizing the supply shock just like 2010-11).

At first the contest featured more sparring than any true combat; the Fed increased its benchmarks as is its playbook to which bonds initially offered only token resistance.

The curve very modestly inverted between the 2s10s spot from March 2022, though never much and only sporadically.

Things heated up last June though, again, it wasn’t yet a true heavyweight fight.

The punches became more intense, the Fed upping its rate hikes to 75 bps while inversions spread and deepened.

The match finally got going in September and October when “something” happened which triggered the first big response from the champ.

Beyond late October, the Fed kept punching but bonds (LT) weren’t budging; yields went sideways to lower even as the FOMC voted for higher.

They would respond, getting in a good one in February upon the release of the January payroll figures backed up by a rash of suddenly “hot” economic statistics. Policymakers fashion them into their strike: forward guidance declaring higher-for-longer.

This was a simple yet effective tactic, tying any economic data that wasn’t downright awful to a “resilient” economy requiring ever-higher interest rates from the Fed. And if any better-than-atrocious statistics were accompanied by any consumer price measure still better than 2%, the greater the punching power.

The hit landed squarely enough, forcing bonds back on their heels. Rates rose especially at the crucial 2-year spot and LT yields followed in somewhat stunned fashion.

It would not last long because within weeks bonds struck back with a massive swing of their own – the banking crisis. This immediately stunned officials into complete silence, even a pause in the rate hikes while at the same time market interest rates would plummet and completely ignore any further action from any central bank anywhere.

This is, in fact, the whole basis for the conflict: what are interest rates?

To bonds or anyone employing intuition and common sense, falling rates especially from a low start are never a good sign. History has conclusively shown them associated only with the worst circumstances, those when deflation and depression have been widely acknowledged: the US in the thirties or Japan in the nineties, aughts, teens, and almost certainly the twenties, too.

But to Economists a central bank must raise rates to fight inflation. Never mind how during genuinely inflationary periods interest rates always go up on their own without any assistance, policymakers far removed from real monetary competence have instead attempted to fill that void with a bastardization of the mechanics.

They believe that a fed funds target isn’t high or low on its own and instead should only be judged in relation to the so-called neutral rate. If the Fed’s benchmarks somehow, someway find themselves above neutral, this would be “restrictive” and allow officials the ability to slow the economy (reducing demand for credit) and theoretically tighten against inflation.

Of course, no one can say for sure what the neutral rate is at any given time which is why it always appears like the Fed is just making things up as it goes. If anyone had a solid idea let alone a calculation for it, they’d be able to say in advance just how high interest rates must go to surpass neutral.  

What happens instead is literal guesswork combined with the worst fallacy in statistics, presuming causation from mere correlation. As stupid as it sounds, the Fed (or ECB) just blindly hikes until it gets the results it wants. When (if) it does, authorities further presume it must’ve been due to the policy. Should that result be consumer price rates at or below 2%, then until it happens policymakers will never be certain if rates are above neutral.

Bond market participants quite naturally scoff at these ridiculous notions more akin to stylized primitive rituals than actual science; resistance to them isn’t really difficult to fathom.

That resistance got taken up a notch or two last autumn in what wasn’t some random coincidence.

While the media spun those events in September as something to do with the UK’s pension funds selling government gilts due to the Bank of England’s good work, anyone really paying attention to the monetary system breaking down immediately recognized what was going on.

That very small list included, believe it or not, at least one of the central banker class.

ECB’s Isabel Schnable recalled in early March, ironically just days before SVB would break, there had been something really wrong in collateral; not in London, rather all over Europe which was too easily spotted in Germany’s top-quality issues:

“…the ‘scarcity premium’ that market participants must pay to obtain these assets [government bonds] has often been considerable, both in the repo and the bond market…in times of heightened uncertainty, when the demand for safe and liquid assets rises sharply, market conditions tend to visibly deteriorate. Last year’s [September] surge in market volatility is a case in point…At times, around half of the repo volume backed by German collateral was trading more than 40 basis points below the general collateral rate.”

The jargon is dense and the concepts can be arcane, even so it really isn’t all that difficult to understand once you overcome those modest impediments. What Ms. Schnable was recounting was nothing other than a collateral run.

During one, no different from any other monetary run, demand for usable currency skyrockets, in this case the best quality collateral. And as demand surges, the price does likewise only when it comes to collateral used in various ways like repo or derivatives, price isn’t nearly as straightforward.

Increasingly scarce issues “trade special” which means that participants are willing to borrow (securities lending that isn’t actually lending, instead hypothecation) good collateral at increasingly unfavorable terms. They will lend cash and accept a growing penalty when doing so: the repo rate they’re lending at well below other market rates.

As collateral strains become particularly acute, more trade special and often deeply so as Schnable was describing. Collateral values compared to cash go up which is why you’d accept so much smaller of a return when lending cash than you would otherwise.

To put it bluntly, the global monetary events in September and October were, in fact, the initial stages of what then became the banking crisis. Realizing this, the bond market then uncorked its first major counterpunch against rate hikes because of the deflationary consequences which would eventually follow, those which included March (and beyond).

Deflation is always associated (in reality if not Economics theories) with higher demand for safe and liquid instruments like government bonds the Federal Reserve would desperately like to drive lower in price (yields higher). In the case of top-quality collateral like Treasuries and German bunds, demand for safe and liquid takes on an additional element beyond flight-to-safety.

This punch/point was only driven further home once SVB then Credit Suisse (global monetary crisis and extreme collateral run, not strictly US regional banks unable to secure themselves against deposit flight) failed in March.

It landed with such great impact it stunned the rate-hikers (and others) into silence.

The fight did not end there, obviously. The Fed has been itching to get itself back up off the mat because consumer price numbers remain elevated, in particular core measures (which tell us nothing useful about the state of the economy or the labor market) which they believe indicate rates still not restrictive.

Officials did so this week with the release of the minutes from their last meeting in mid-June (the pause). They contained first an acknowledgement there will indeed be a recession and one which is almost certain to begin this year (assuming it hasn’t started already). However, the text also noted a majority of the committees’ members remain committed to further rate hikes anyway!

In other words, announcing ahead of time there will be rate hikes even in recession.

This throws off the timing for the widely anticipated Fed pivot. By stating officials won’t even consider anything like rate cuts unless there’s something worse than a “mild” recession, it will now take policymakers longer to realize their error, requiring an even worse and more widespread deterioration in the data they watch for it to happen. As a result, the pivot gets pushed a little further into the future which means the 2-year spot on the curve has to acknowledge the punch.

As 2-year yields have gone up, LT rates have backed up, too, a successful counterstrike for higher rates after having suffered the blow from the first stage of the banking crisis which saw them fall sharply.

It was not a knockout, though. Inversions remain and are as bad as ever, which shows resistance continues to be strong and for all the same reasons.

The bond market is now biding time for its next opportunity to counter with what is looking to be one final fight-ending uppercut.

And we know where it will come from: collateral likely tied to CRE and CMBS.

The Fed had the upper hand initially but got bruised badly last September. The market took the initiative which only hardened the resolve of the neutral-rate guessers. But after they landed a successful punch in February, bonds came back with a whopper of SVB and Credit Suisse leaving Jay Powell to attempt what is no better than a rope-a-dope with this rate-hiking-in-recession tactic.

Even if he is successful, we all lose.

Sure, he’ll claim he traded a mild recession for the end of inflation, but that was never what this fight was ever really for. At best, we get a modest contraction for consumer price pressures that were only ever going to be transitory. This is what the fight has been the whole time, not how it ends but what it even was.

It was never neutral. 

https://www.zerohedge.com/markets/even-if-jerome-powell-successful-we-still-lose

Johnson & Johnson sues researchers who linked talc to cancer

  Johnson & Johnson has sued four doctors who published studies citing links between talc-based personal care products and cancer, escalating an attack on scientific studies that the company alleges are inaccurate.

J&J's subsidiary LTL Management, which absorbed the company's talc liability in a controversial 2021 spinoff, last week filed a lawsuit in New Jersey federal court asking it to force three researchers to "retract and/or issue a correction" of a study that said asbestos-contaminated consumer talc products sometimes caused patients to develop mesothelioma.

One of the researchers, Richard Kradin, declined to comment. The other two, Theresa Emory and John Maddox, did not respond to requests for comment. Lawyers who have represented the three researchers in similar litigation in the past declined to comment.

J&J is facing more than 38,000 lawsuits alleging that the company's talc products, including its Baby Powder, were contaminated by asbestos and caused cancers including ovarian cancer and mesothelioma. J&J is attempting to resolve those lawsuits, as well as any future talc lawsuits, through an $8.9 billion settlement in bankruptcy court.

J&J says that its talc products are safe and do not contain asbestos.

J&J has stopped selling talc-based Baby Powder in favor of cornstarch-based products, citing an increase in lawsuits and "misinformation" about the talc product's safety.

The company in 2021 began exploring bankruptcy as a potential solution to the lawsuits, which saw a mixed record at trial, including several defense wins but also a $2.1 billion verdict awarded to 22 women who blamed their ovarian cancer on asbestos in the company's talc products. J&J said in bankruptcy court filings in April that the costs of its talc-related verdicts, settlements and legal fees have reached about $4.5 billion.


Cdc-free Vaccines Through This Temporary Program Will Not Be Available

 CDC-FREE VACCINES THROUGH THIS TEMPORARY PROGRAM WILL NOT BE AVAILABLE AFTER DECEMBER 2024

https://www.marketscreener.com/news/latest/CDC-FREE-VACCINES-THROUGH-THIS-TEMPORARY-PROGRAM-WILL-NOT-BE-AVA-8230--44332535/

China stocks jump at close after govt signals support to tech giants

 China and Hong Kong stocks jumped on Thursday, led by tech giants, after authorities sent another strong signal that a years-long crackdown on its tech industry is over, and lower-than-expected U.S. inflation data also boosted sentiment.

** China's blue-chip CSI 300 Index rose 1.4%, logging its biggest daily rise in nearly one month, while the Shanghai Composite Index added 1.3% at close.

** Hong Kong's Hang Seng Index and the Hang Seng China Enterprises Index both climbed 2.6%.

** Other Asian shares and bonds also rallied, while the dollar nursed heavy losses as a surprisingly low reading on U.S. inflation stoked speculation the end of the post-pandemic tightening cycle is in sight.

** Chinese tech giants listed in Hong Kong rallied 3.8% after Premier Li Qiang urged the companies to support a slowing economy, adding to signs that a years-long crackdown on the sector is over.

** Tai Hui, APAC chief market strategist, J.P. Morgan Asset Management, is positive on China internet stocks for the second half and believes these companies will deliver decent results as they have adjusted their business models.

** China's exports fell 12.4% in June year-on-year, customs data showed on Thursday, worse than economists' forecast of a 9.5% contraction in a Reuters poll.

** "Export growth dropped further as external demand weakened," said Zhiwei Zhang, chief economist at Pinpoint Asset Management. "The big question in the next few months is whether domestic demand can rebound without much stimulus from the government."

** Elizabeth Kwik, investment director of Asian equities at abrdn, said there are broader concerns influencing the China stock market, "such as the weak consumer recovery in the mainland, as well as concerns over U.S.-China geopolitical dynamics".

** Credit Suisse upgraded Chinese equities to "overweight" on Thursday and struck a more positive note on the country's economic growth, as it expects stimulus measures from the government amid a drop-off in manufacturing.

** In onshore markets, shares in consumer staples, semiconductors, information technology and non-ferrous metal added more than 2% each.

https://www.marketscreener.com/news/latest/China-stocks-jump-at-close-after-govt-signals-support-to-tech-giants--44327856/